BioSpace News Archive

Minerva Neurosciences, Inc. today announced Dr. Jay Saoud’s retirement and transition to an advisory role and Dr. Ramana Kuchibhatla’s appointment as Senior Vice President and Head of Research & Development, both effective September 16, 2021.

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Monday, September 13, 2021, at 4:15p.m. Eastern Time.

Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, , today announced it will exhibit at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2021 – which brings together the world’s leading experts in heart failure from September 10-13, 2021.

Frontage Shanghai announced the acquisition of 70% equity interest in Wuhan Heyan Biomedical Technology Co., Ltd.

Simulations Plus, Inc. today announced that chief executive officer Shawn O’Connor will be presenting at two upcoming investor conferences: BofA Securities 2021 Tech Solutions for Drug Discovery Conference on Monday, September 20, 2021.

Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that Corey Fishman, Chief Executive Officer, will provide a company overview and business update at the H.C. Wainwright 23rd Annual Virtual Global Investment Conference.

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that is has submitted a Pre-Investigational New Drug application (Pre-IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of Ampligen as a potential infusion therapy for Post-COVID-19 Cognitive Dysfunction (PCCD).

Royal Biologics, an ortho-biologics company focused on Autologous and Live Cellular solutions, has announced FDA 510K approval of their Maxx™-PRP concentration system.

Today, Eirion Therapeutics, Inc., an aesthetic dermatology company headquartered in Woburn, Massachusetts, announced that HTL Biotechnology, the worldwide leader in biotechnology solutions using hyaluronic acid and other biopolymers, will become Eirion’s exclusive botulinum active pharmaceutical ingredient (API) manufacturer.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in Citi’s 16th Annual BioPharma Virtual Conference 2021 investor conference.